ArticleBMC cardiovascular disorders2025
The elevated levels of soluble growth stimulation expressed gene 2 are associated with coronary atherosclerotic plaque destabilization in unstable angina patients: a case control study.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlaque destabilization and rupture are the primary triggers of acute coronary syndrome (ACS). Soluble growth stimulation expressed gene 2 (sST2) has been implicated in cardiovascular disease. We aimed to investigate the association between circulating sST2 levels and features of coronary plaque destabilization assessed by optical coherence tomography (OCT) in patients with unstable angina (UA).
methodsThis study enrolled 122 patients admitted with UA and 107 age- and sex-matched healthy controls. All UA patients underwent standard coronary angiography and OCT imaging to identify features indicative of plaque destabilization. Plasma sST2 levels were measured in all participants using an immunofluorescence assay. Associations between sST2 levels, clinical characteristics, and factors predicting OCT-defined plaque destabilization were analyzed.
resultssST2 levels were significantly higher in UA patients compared to healthy controls (p < 0.001). Among UA patients, sST2 levels were significantly elevated in those with OCT-defined plaque destabilization features compared to those without (p < 0.001). In multivariable logistic regression analysis, elevated sST2 levels emerged as an independent factor associated with the presence of OCT-defined plaque destabilization (p = 0.013).
conclusionsCirculating sST2 levels are elevated in UA patients and independently associated with features of coronary plaque destabilization identified by OCT. These findings suggest sST2 may be a novel biomarker reflecting plaque destabilization in patients with UA, potentially aiding in risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.